ArticlePhysical and engineering sciences in medicine2026
Dosimetric impact of knowledge-based automated planning using HyperArc for angiosarcoma of the scalp.
Article in Physical and engineering sciences in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
This study aimed to automate and standardize treatment planning by comparing the dosimetric performance of conventional volumetric modulated arc therapy (C-VMAT) with that of HyperArc optimized using the knowledge-based RapidPlan model trained with the HyperArc plan (RP-HA) for total scalp irradiation (TSI) in the treatment of angiosarcoma of the scalp (AS). Additionally, this study compared the dosimetric performance of RP-HA with that of non-coplanar VMAT optimized using the same model (RP-NC-VMAT). From 40 patients with AS who had undergone TSI, 20 patients were selected for HyperArc planning and RapidPlan model training. The remaining 20 patients had treatment plans generated using three different methods (C-VMAT, RP-NC-VMAT, and RP-HA). The prescription doses were 70 and 56 Gy in 35 fractions of the target volumes, including gross tumor and whole scalp, respectively, using the simultaneous integrated boost technique. The dose distribution, dosimetric parameters, and dosimetric accuracy of each treatment plan were evaluated and compared between methods. None of the three methods exceeded the acceptable limits for all constraint parameters of the target and organs at risk. The RP-HA plan provided a significantly lower mean brain dose (10.96 ± 1.54 Gy) than the C-VMAT and RP-NC-VMAT plans (18.06 ± 2.17 Gy and 12.36 ± 2.12 Gy). The dose received by 0.1 cm
Indexed as
Identifiers
42479382What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.